# Table of Contents

**Management of Pain, Agitation/Sedation, Delirium, Immobility, and Sleep Disruption and Neuromuscular Blockade in Adult Intensive Care Unit Patients** ................................................................. 1

Pain, Agitation/Sedation, Delirium, Immobility, and Sleep Disruption (PADIS) in the ICU; Pain in the ICU; Agitation in the ICU; Delirium in the ICU; ABCDE Bundle; Post-Intensive Care Syndrome; Neuromuscular Blockade in the ICU

**Supportive and Preventive Medicine** ................................................................. 53

Key Aspects in the General Care of All Critically Ill Patients; Stress Ulcer Prophylaxis; Prophylaxis Against Deep Venous Thrombosis or Pulmonary Embolism; End-of-Life Care

**Fluids, Electrolytes, Acid-Base Disorders, and Nutrition Support** ...... 83

Fluids and Electrolytes; Acid-Base Disorders; Nutrition Support

**Pulmonary Disorders** ..................................................................................... 139

Acute Respiratory Distress Syndrome; Intubation; Mechanical Ventilation; Cystic Fibrosis; Pulmonary Hypertension; Asthma Exacerbation; Acute Chronic Obstructive Pulmonary Disease Exacerbation

**Toxicology** .................................................................................................. 179

Epidemiology; Emergency Evaluation and Management; Gastric Decontamination/Enhanced Elimination; Acetaminophen; Salicylates; Opioids; Loperamide; Alcohols (Methanol and Ethylene Glycol); Alcohol Withdrawal; β-Blockers and Calcium Channel Blockers; Digoxin; Antidepressants; Atypical Antipsychotics; Lithium; Oral Hypoglycemics; Drugs of Abuse

**Acute Kidney Injury and Renal Replacement Therapy in the Critically Ill Patient** ............................................................................................................. 225

Acute Kidney Injury; Renal Replacement Therapies

**Practice Administration and Development:**

**Protocol Development and Quality Improvement** ............................................. 245

Policy and Guideline Development; Gap Analysis; Quality Assurance, Quality Performance Improvement; Medication Use Evaluation; Documentation Processes Used for Critical Care Pharmacy Services

**Research Design, Biostatistics, and Literature Evaluation** ....................... 283

Bioethics; Practical Challenges to Critical Care Research; Study Design; Statistical Analysis; Noninferiority Trial Design; Application of Knowledge to Patient Care
# Table of Contents

**Neurocritical Care** ............................................................................................................. 305
Hypotension; Hypernatremia; Status Epilepticus; Central Nervous System Infection; Intraventricular
Antibiotic Administration; Ventricular Pressure Treatment; Paroxysmal Sympathetic Hyperactivity (I.E.,
“Storming”); Acute Ischemic Stroke, Intracerebral Hemorrhage; Subarachnoid Hemorrhage; Interventional
Endovascular Management; Acute Spinal Cord Injury; Brain Tumors; Critical Illness Polyneuropathy (CIP);
Guillain-Barré Syndrome (GBS); Myasthenia Crisis; Serotonin Syndrome; Neurologic Monitoring Devices

**Acute Cardiac Care** ............................................................................................................. 357
Advanced Adult Cardiac Life Support; Hypertensive Crisis

**Cardiovascular Critical Care** .......................................................................................... 407
Cardiovascular Fundamentals Overview; Hemodynamic Management and the Heart; Cardiogenic Shock; Acute
Coronary Syndromes; Arrhythmias and Antiarrhythmics; Heart Failure; Valvular Heart Disease; Advanced
Therapies for Heart Failure and Cardiogenic Shock

**Shock Syndrome I: Introduction, Vasodilatory, and Sepsis** .................................................. 467
Introduction; Monitoring Techniques; Differentiation of Shock States; Resuscitation Parameters and End
Points; Agents to Treat Shock – Fluids and Vasoactive Agents; Vasodilatory and Distributive Shock; Sepsis

**Shock Syndrome II: Hypovolemic, Critical Bleeding, and Obstructive** .................................. 525
Hypovolemic Shock; Obstructive Shock

**Hepatic Failure/GI/Endocrine Emergencies** ................................................................. 567
Acute Liver Failure; Acute Pancreatitis; Gastrointestinal Fistulas; Postoperative Ileus; Postoperative Nausea
and Vomiting; Upper Gastrointestinal Bleeding; Endocrine Emergencies

**Infectious Diseases I** ........................................................................................................... 627
Ventilator-Associated Pneumonia; Central Line–Associated Bloodstream Infections; Influenza; Catheter-
Associated Urinary Tract Infections; Complicated Intra-abdominal Infection; Acute Pancreatitis; Clostridium
difficile Infection; Wound Infection; Stevens-Johnson Syndrome and Toxic Epidermal Necrolysis

**Infectious Diseases II** .......................................................................................................... 683
Quality Improvements; Bacterial Meningitis; Antimicrobial Stewardship; Rapid Diagnostic Tests; Interpreting
Susceptibility Reports; Mechanisms of Antibacterial Resistance and Treatment of Multidrug-Resistant
Pathogens; Immunocompromised Patients; Human Immunodeficiency Virus (HIV)/Acquired Immune Deficiency
Syndrome (AIDS) in Critically Ill Patients; Antifungal Therapy

**Pharmacokinetics/Pharmacodynamics** .............................................................................. 749
Routes of Administration; Absorption; Distribution; Metabolism; Excretion; Pharmacodynamics; Therapeutic
Drug Monitoring

**Practice Administration and Development:**
**Pharmacoeconomics and Safe Medication Use** .............................................................. 783
Pharmacoeconomics; Drug-Related Events: Medication Errors, ADEs and ADRs, Side Effects, Preventable
ADEs; Clinical Practice Guidelines: Safe Medication Use in the ICU; Drug Interaction Surveillance and
Prevention; Formulary Proposal
Critical Care Pharmacy Evolution and Validation, Practice Standards, Training, and Professional Development ........ 819
Landmark Events in Critical Care Medicine/Pharmacy; Validation of Critical Care Pharmacy as a Specialty; Critical Care Pharmacy Growth; Studies Documenting the Association of Critical Care Pharmacy Services with Favorable Health Care Outcomes; Practice Standards for Critical Care Pharmacy; Training of Critical Care Pharmacists; Continuing Professional Development; Core Knowledge Base Areas for Pharmacists Caring for Critically Ill Patients; Dissemination of Critical Care Knowledge

Additional Resources

Policy, Practice and Regulatory Issues ......................... 861
Congressional Overview, Committees with Jurisdiction over Health-Related Policy, and the Legislative Process; U.S. Government Departments and Agencies with Primary Regulatory Impact on the Practice of Pharmacy; Recent Legislative Activity with Regulatory and Health Policy Implications; the U.S. Food and Drug Administration and the Prescription Drug Approval Process; Accrediting Organizations and Quality Improvement Efforts; Institutional Medication Use Policy Considerations; Institutional Review Board Implications for Clinical Practice and Research; Investigational Drug Service

Communication Strategies in Pharmacy ......................... 905
Communicating Verbally with Patients and Caregivers; Selecting Written Patient Educational Materials; Alternative Methods of Communicating with Patients; Communicating with Other Health Care Professionals; Documenting in the Medical Record; Opportunities for Patient Advocacy Outside the Health Care System